ALACRITA STRENGTHENS CAMBRIDGE, MA TEAM TO ADVISE CLIENTS ON CLINICAL DEVELOPMENT STRATEGY, PLANNING AND OPERATIONS
Appoints Edward G. Garmey, MD as Consultant
Cambridge, MA, 23 November 2015 – Alacrita, the life sciences consulting firm, today announced that it has appointed Edward Garmey, M.D., as a consultant in its Cambridge, MA office.
Dr. Garmey will join William Slichenmyer, M.D., ScM. in the firm’s oncology drug development practice and the move helps consolidate Alacrita’s position as a leading provider of clinical development advice to life science companies developing novel therapeutic agents. Dr. Garmey was formerly Chief Medical Officer and Senior Vice President at Cerulean Pharma, Inc., a clinical stage oncology company focussed on the development of nanopharmaceutical-drug-conjugates differentially directed to cancer cells. During his tenure at Cerulean, the company completed a successful IPO and launched eight clinical trials.
Dr. Garmey joins a growing team of specialists at Alacrita who have distinguished track records of developing novel therapeutic agents. Alacrita is supported by a team of Associates across Europe and the U.S., all of whom are carefully selected for their deep life science industry experience and expertise. The firm supports clients with product development, transaction support and transatlantic expansion advice.
Edward Garmey said “I am delighted to be joining the Alacrita team, which has an impressive track record of advising client organizations in the life sciences. The pace of innovation in our industry is accelerating while the complexity of oncology clinical development is increasing. I look forward to engaging with our clients on their drug development and commercialization efforts.”
Rob Johnson, Managing Partner at Alacrita, said: “We are delighted to welcome Edward to our product development practice as we build a best-in-class consulting practice to help companies develop better therapeutics. Edward is an experienced executive with recent, hands-on expertise of developing novel anticancer drugs. He has deep and broad knowledge of the drug development process and a sound understanding of the challenges faced by senior management. He joins a high calibre team of seasoned consultants and underlines our commitment to providing exceptionally high quality advice to the industry.”